The effects of metamizole on hematopoietic progenitor cells: Suppression of hematopoiesis stimulation in vitro

Abstract

BACKGRAUND: There is evidence that the adverse effects of metamizole occur due to the effect of the drug on the hematopoietic stem/progenitor cells, and therefore, the disruption of hematopoiesis. Therefore, our study aimed to evaluate the effects of metamizole on hematopoietic stem/progenitor cells using cell culture techniques. MATERIAL AND METHODS: In our study, samples were taken from stem cell products of healthy allogeneic stem cell transplant donors. The colony-forming unit (CFU) assay was used for the cells obtained from these samples. In addition, the drug effects on cell proliferation were evaluated with the MTT. Furthermore, the cell colonies were labelled with immunofl uorescent antibodies and the effects of metamizole on cell types formed in culture were evaluated. RESULTS: We determined that metamizole negatively affects the proliferation of cells, especially starting from 10 μM. As a result of the evaluation of colonization, we saw that the number of colonies decreased with increasing concentrations. Granulocyte-macrophage colonies were more affected at increasing concentrations than other colonies. As a result of the evaluations of our in vitro study, it was also shown as an important fi nding that the individual effects of the drug were highly variable. CONCLUSION: CFU method can be used as a suitable method to investigate the effects of drugs and toxic substances on hematopoiesis. We also think it may be suitable for pre-analysing hematopoietic side effects in new drug research. In addition, using stem cell samples in studies may contribute more easily to the in vitro simulation of hematopoietic differentiations (Fig. 7, Ref. 29).

Do non-steroidal anti-inflammatory drugs affect the release of GnRH via neuronal markers?

“…On the other hand, some studies with various cells report that dipyrone may be apoptotic and have antiproliferative properties. Since the use of dipyrone has been restricted in the USA and many countries, especially in children, due to its side effects, such as aplastic anaemia and agranulocytosis, there are fewer studies than other NSAIDs with dipyrone [13,14]. GT1-7 cells, developed by genetically targeting the tumorigenesis of mouse hypothalamic neurons, have several neuronal features such as elongation of neurites, secretion of gonadotropin-releasing hormone (GnRH), expression of neuron-speci c receptors and proteins [15].…”

One hundred years of dipyrone (metamizole): the recent evidence on its safety

“…Also, metamizole may still be associated with an increased risk of blood dyscrasias, including induced neutropenia and agranulocytosis, defined as an absolute circulating neutrophil count of less than 500 µL [17]. Probably because it can affect cells proliferation and reduce the erythroid colonies [18]. Blood disorders were the reason why dipyrone was banned in the 1980s in the United States, and was followed by other countries such as the United Kingdom, Sweden, and Denmark [19].…”